Not provided
Not provided
Not provided
Not provided
Not provided
No patients were successfully recruited
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare a new treatment for nosebleeds to the treatment that has been used for many years.
Nosebleeds are a common condition which affect many Americans every day.The standard treatment in this hospital for nosebleeds that do not resolve with squeezing the nose or nasal spray is to place a nasal packing (aka nasal tampon) into the nose. This is an effective treatment in most cases, but patients may find it to be uncomfortable. The investigators will be comparing the standard nasal packing with a new type of powder which may also stop nosebleeds.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Microporous Polysaccharide Hemospheres (MPH) | Active Comparator | Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel. |
|
| Merocel (Control) | Active Comparator | Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Microporous Polysaccharide Hemospheres | Device | Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of subjects with resolution of bleed | Resolution of bleeding is determined by cessation of blood flow anteriorly from the nares as well as posteriorly in the pharynx. This will be determined by the otolaryngology resident or attending managing the patient during the study. | 15 minutes (average time to resolve bleeding) |
| Measure | Description | Time Frame |
|---|---|---|
| Time until resolution of bleeding | Number of minutes it takes to resolve bleeding comparing the Arista powder group versus the Merocel tampon group. | 15 minutes (average time to resolve bleeding) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Oswaldo Henriquez Ajami, MD | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emory University Department of Otolaryngology Clinic | Atlanta | Georgia | 30308 | United States |
Not provided
| ID | Term |
|---|---|
| D004844 | Epistaxis |
| ID | Term |
|---|---|
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D006470 | Hemorrhage |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Nasal Tampon | Device | 8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician. |
|
|
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |